DRMA Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 geg. 2024 @ 23:00):

Stats
Šios dienos apimtis	6 886.00
Vidutinė apimtis	126 947
Rinkos kapitalizacija	2.21M
EPS	$0 ( 2024-02-20 )
Kita pelno data	( $-0.360 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.120
ATR14	$0.00400 (1.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-04	Mento Steven J	Buy	10 000	Stock Option (Right to Buy)
2024-01-04	Proehl Gerald T	Buy	125 000	Stock Option (right to buy)
2024-01-04	Fisher Mary	Buy	10 000	Stock Option (Right to Buy)
2024-01-04	Scott Kathleen D.	Buy	10 000	Stock Option (Right to Buy)
2024-01-04	Sandler Andrew Seth	Buy	10 000	Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 98 transactions
Buy: 8 169 572 \| Sell: 872 238

Dermata Therapeutics, Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
SVAC	0.964
PAIC	0.955
TLGT	0.926
SVOK	0.917
RMRM	0.917
SPRT	0.885
EARS	0.875
PROG	0.873
BLPH	0.863
FORE	0.859

10 Labiausiai neigiamai susiję koreliacijos
NETE	-0.977
AMRB	-0.924
MMAC	-0.903
RAVN	-0.892
SRAC	-0.88
ANIK	-0.866
BOCH	-0.85
ATHN	-0.849
CPTN	-0.839
ODT	-0.835

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Dermata Therapeutics, Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-2.67

FY	2023
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-2.67

FY	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-13.92

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-2.43

Financial Reports:

No articles found.

Dermata Therapeutics,

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.